Literature DB >> 1606785

Controversies in bioequivalence studies.

V W Steinijans1, D Hauschke, J H Jonkman.   

Abstract

Mesh：

Year:  1992        PMID： 1606785     DOI： 10.2165/00003088-199222040-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  22 in total

1.  Symmetrical confidence intervals for bioequivalence trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1976-12       Impact factor: 2.571

2.  Sample size determination for bioequivalence assessment by means of confidence intervals.

Authors:  E Diletti; D Hauschke; V W Steinijans
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-01

Review 3.  Striving for standards in bioequivalence assessment: a review.

Authors:  H U Schulz; V W Steinijans
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-08

4.  Update on the statistical analysis of bioequivalence studies.

Authors:  V W Steinijans; D Hauschke
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-03

5.  Power of the two one-sided tests procedure in bioequivalence.

Authors:  K F Phillips
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

6.  Bioequivalence studies: single vs multiple dose.

Authors:  V W Steinijans; R Sauter; J H Jonkman; H U Schulz; H Stricker; H Blume
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-05

7.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

8.  Galenical development of a new sustained-release theophylline pellet formulation for once-daily administration.

Authors:  G Benedikt; V W Steinijans; R Dietrich
Journal:  Arzneimittelforschung       Date:  1988-08

9.  Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption.

Authors:  A Karim; T Burns; D Janky; A Hurwitz
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

Review 10.  Food interactions with sustained-release theophylline preparations. A review.

Authors:  J H Jonkman
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447
View more
  13 in total

1.  Sample size determination for bioequivalence assessment using a multiplicative model.

Authors:  D Hauschke; V W Steinijans; E Diletti; M Burke
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence.

Authors:  Pietro Fagiolino
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jan-Mar       Impact factor: 2.441

Review 3.  Bioequivalence assessment of generic drugs: an American point of view.

Authors:  R Patnaik; L J Lesko; K Chan; R L Williams
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 4.  The influence of food on the absorption and metabolism of drugs: an update.

Authors:  L Williams; D P Hill; J A Davis; D T Lowenthal
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jul-Sep       Impact factor: 2.441

5.  A Model for Predicting the Interindividual Variability of Drug-Drug Interactions.

Authors:  M Tod; L Bourguignon; N Bleyzac; S Goutelle
Journal:  AAPS J       Date:  2016-12-06       Impact factor: 4.009

6.  Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet-injection: comparison with conventional needle-injection.

Authors:  A Verhagen; J T Ebels; A A Dogterom; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers.

Authors:  L Tennezé; V Daurat; A Tibi; P Chaumet-Riffaud; C Funck-Brentano
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

8.  Which bioequivalence study for a racemic drug? Application to milnacipran.

Authors:  D Deprez; D Chassard; P Baille; A Mignot; H L Ung; C Puozzo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

9.  Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses.

Authors:  J S Bertino; A N Nafziger; M Wong; L Stragand; C Puleo
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  Lansoprazole does not affect the bioavailability of oral contraceptives.

Authors:  W Fuchs; R Sennewald; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.